Blueprint May Corner EGFR Exon Mutated Lung Cancer Market With Lengo Buyout

Blueprint Medicines Corporation acquired Lengo Therapeutics, a privately held biotech with an early-stage asset that combined with two of Blueprint’s own pipeline candidates could enable it to address roughly 97% of epidermal growth factor receptor (EGFR) exon mutation-related lung cancer cases. The Cambridge, MA-based firm said on 29 November it has agreed in principle to acquire Lengo for $250m in cash up front plus up to $215m in potential approval and sales-based milestones.

Lengo’s preclinical LNG-451 is an oral precision therapy designed to address non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, which Blueprint says accounts for about 12% of EGFR exon mutation NSCLC cases. Blueprint’s pipeline already includes two agents aimed at exon 19 or exon 21 mutations, which account for about 85% of EGFR-driven NSCLC cases